This is a working overview of peptide mapping, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-17. Anything still debated is marked as such rather than presented as settled.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
==== Diabetes ==== The high doses of nicotinic acid used to treat hyperlipidemia have been shown to elevate fasting blood glucose in people with type 2 diabetes. Long-term nicotinic acid therapy was also associated with an increase in the risk of new-onset type 2 diabetes.
Matrikines are a large and somewhat loosely defined group of peptides and small proteins, encompassing both endogenous signalling factors important in wound healing and tissue remodeling, and synthetically produced versions of these along with related analogues and derivatives, which are used mainly for cosmetic applications as well as for scientific research and with some medical indications.
1938: American botanists Elzada U Clover and Lois Jotter were the first women to catalog plant life in the Grand Canyon and the first to raft the entire length of the Colorado River 1939: Austrian-Swedish physicist Lise Meitner, along with Otto Hahn, led the small group of scientists who first discovered nuclear fission of uranium when it absorbed an extra neutron; the results were published in early 1939. 1939: French physicist Marguerite Perey discovered the chemical element francium. 1939: Indian biochemist Kamala Sohonie became the first Indian woman to receive a PhD in a scientific discipline in 1939.
=== Cancer === Preliminary studies suggest that FFAR2 may be involved in some types of cancer. 1) One study found that FFAR2 levels were elevated in human stomach and colorectal cancers although another study reported that FFAR2 levels were markedly deceased in human colorectal cancer. These results suggest that FFAR2 may promote the development and/or progression of human stomach cancer but its impact on human colorectal cancer requires further study. 2) In a dextran sulfate sodium-induced model of inflammation-associated colon cancer, FFAR2 knockdown mice developed larger and more tumors than control mice. This study suggests that FFAR2 inhibits the development and/or progression of inflammation-associated colon carcinoma in mice; its role in human inflammation-associated colorectal cancer (e.g., colorectal cancer developing in ulcerative colitis) has not been clarified. 3) Compared to their normal lung tissues, the lung cancer tissues of 42 patients had lower levels of FFAR2 but not FFAR1, FFAR3, or FFAR4. 4) Butyric acid inhibited the proliferation of and triggered apoptosis in cultured human A549 lung cancer cells; further studies in A549 as well as H1299 human lung cancer cells found that propionic acid inhibited their stimulated migration, invasiveness, and colony growth in cell culture assays but did not do so in FFAR2 gene knockout A549 or H1299 cells. These results suggest that FFAR2 may inhibit the development and/or progression of human lung cancer.
The leaves of the coca plant contain alkaloids that—when extracted chemically—are the source for cocaine base. The amount of coca alkaloid in the raw leaves is small, however. A cup of coca tea prepared from one gram of coca leaves (the typical contents of a tea bag) contains approximately 4.2 mg of organic coca alkaloid. (In comparison, a typical dose (a "line") of cocaine contains between 20 and 30 milligrams.) Owing to the presence of these alkaloids, coca tea is a mild stimulant; its consumption may be compared to consumption of a moderately strong cup of coffee or tea. The coca alkaloid content of coca tea is such that the consumption of one cup of coca tea can cause a positive result on a drug test for cocaine, however. Similar to decaffeination in coffee, coca tea can be decocainized. Just as decaffeinated coffee retains a small quantity of caffeine, decocainized coca tea will still contain a small quantity of organic coca alkaloids. There is little information on the pharmacological and toxicological effects of consuming coca tea. A chemical analysis by solid-phase extraction and gas chromatography–mass spectrometry (SPE-GC/MS) of Peruvian and Bolivian tea bags indicated the presence of significant amounts of cocaine, the metabolite benzoylecgonine, ecgonine methyl ester and trans-cinnamoylcocaine in coca tea bags and coca tea. Urine specimens were also analyzed from an individual who consumed one cup of coca tea and it was determined that enough cocaine and cocaine-related metabolites were present to produce a positive drug test.
Sources: en.wikipedia.org
I do not respect Christian beliefs. I think they are ridiculous. If we could get rid of them we could more easily get down to the serious problem of trying to find out what the world is all about. Crick once joked, "Christianity may be OK between consenting adults in private but should not be taught to young children." In his book Of Molecules and Men, Crick expressed his views on the relationship between science and religion. After suggesting that it would become possible for a computer to be programmed so as to have a soul, he wondered: at what point during biological evolution did the first organism have a soul? At what moment does a baby get a soul? Crick stated his view that the idea of a non-material soul that could enter a body and then persist after death is just that, an imagined idea. For Crick, the mind is a product of physical brain activity and the brain had evolved by natural means over millions of years. He felt that it was important that evolution by natural selection be taught in schools and that it was regrettable that English schools had compulsory religious instruction. He also considered that a new scientific world view was rapidly being established, and predicted that once the detailed workings of the brain were eventually revealed, erroneous Christian concepts about the nature of humans and the world would no longer be tenable; traditional conceptions of the "soul" would be replaced by a new understanding of the physical basis of mind.
== Pharmacology == Acebutolol is a cardioselective beta-1 blocker which also considered a partial agonist due to its intrinsic sympathomimetic activity (ISA). This means it provides low-grade beta stimulation at rest but acting as typical beta-blockers when sympathetic activity is high. Among other drugs in the beta-blocker class, Acebutolol will provide beta-blockade effects to a lesser extent. Due to its cardioselectivity, Acebutolol is more suitable than non-cardioselective beta-blockers, in a patient with asthma or chronic obstructive pulmonary disease (COPD) who needs treatment with a beta-blocker. This cardio-specificity will minimize the anti-hypertensive effects as seen with non-specific beta blockers such as Propanalol and Nadolol. (For these reasons, it may be a beta-blocker of choice in inclusion in Polypill strategies). In doses lower than 800 mg daily its constricting effects on the bronchial system and smooth muscle vessels are only 10% to 30% of those observed under propranolol treatment, but there is experimental evidence that the cardioselective properties diminish at doses of 800 mg/day or more. The drug has lipophilic properties and therefore crosses the blood–brain barrier. Acebutolol has no negative impact on serum lipids (cholesterol and triglycerides). No HDL decrease has been observed. In this regard, it is unlike many other beta-blockers which have this unfavourable property.
=== ATLAS and P-body === ATLAS and P-body (known as Blue and Orange to GLaDOS) are player characters in the co-op campaign of Portal 2. They are two robots that cannot speak and can only produce grunts, which are voiced by Dee Bradley Baker. They are equipped with their own portal guns which bears the colour of its user (blue and purple for ATLAS, yellow and red for P-body). Atlas and P-Body are described as masculine and feminine, respectively, as stated by Chet Faliszek in an interview. During the campaign, GLaDOS calls them Blue and Orange, respectively, and constantly tries to ruin their relationship by awarding one and ignoring the other. GLaDOS sends ATLAS and P-body into four areas to access data discs. Once done, they are blown up, as GLaDOS claims it is the only way they can be retrieved from these areas. Later, GLaDOS commands them to retrieve a certain "surprise" in an area. They go in search, only to find hundreds of thousands of other test subjects in suspended animation. After the co-op campaign is finished, GLaDOS quotes that they saved science. ATLAS and P-body begin to celebrate, only to be promptly blown up by GLaDOS. In the DLC campaign "Peer Review", ATLAS and P-body are reactivated by GLaDOS one week after the original co-op campaign, during which GLaDOS has already wiped out all of the found test subjects in her attempts to turn them into "killing machines". The two robots are sent to find a saboteur that has taken control of a prototype central core and is causing problems in the facility.
He had wanted to say: "You sound as though from the tomb", but instead he told Thomas that he sounded like Louis Armstrong. Later, Thomas went drinking with Reitell at the White Horse and, feeling sick again, returned to the hotel. Feltenstein came to see him three times that day, administering the cortisone secretant ACTH by injection (a tropic peptide hormone produced and secreted by the anterior pituitary gland) and, on his third visit, half a grain (32.4 milligrams) of morphine sulphate. This amount was three times more than was medically appropriate and was, by affecting Thomas's breathing and consequently the oxygen supply to his brain, the precipitating cause of the coma from which he would never awake. After Reitell became increasingly concerned and telephoned Feltenstein for advice he suggested she get male assistance, so she called upon the painter Jack Heliker, who arrived before 11 pm. At midnight on 5 November, Thomas's breathing became more difficult and his face turned blue. Reitell phoned Feltenstein who arrived at the hotel at about 1 am, and called for an ambulance. It then took another hour for the ambulance to arrive at St. Vincent's, even though it was only a few blocks from the Chelsea. Thomas was admitted to the emergency ward at St Vincent's Hospital at 1:58 am. He was comatose, and his medical notes state that "the impression upon admission was acute alcoholic encephalopathy damage to the brain by alcohol, for which the patient was treated without response".
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.